- Home
- NUVB vs TRNS Comparison
NUVB vs TRNS Comparison
Compare NUVB & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- TRNS
- Stock Information
- Founded
- NUVB 2018
- TRNS 1964
- Country
- NUVB United States
- TRNS United States
- Employees
- NUVB N/A
- TRNS N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- TRNS Electrical Products
- Sector
- NUVB Health Care
- TRNS Industrials
- Exchange
- NUVB Nasdaq
- TRNS Nasdaq
- Market Cap
- NUVB 679.9M
- TRNS 748.7M
- IPO Year
- NUVB N/A
- TRNS N/A
- Fundamental
- Price
- NUVB $2.09
- TRNS $89.88
- Analyst Decision
- NUVB Strong Buy
- TRNS Buy
- Analyst Count
- NUVB 6
- TRNS 4
- Target Price
- NUVB $7.83
- TRNS $108.67
- AVG Volume (30 Days)
- NUVB 8.9M
- TRNS 126.0K
- Earning Date
- NUVB 08-04-2025
- TRNS 07-28-2025
- Dividend Yield
- NUVB N/A
- TRNS N/A
- EPS Growth
- NUVB N/A
- TRNS N/A
- EPS
- NUVB N/A
- TRNS 1.57
- Revenue
- NUVB $10,957,000.00
- TRNS $278,421,000.00
- Revenue This Year
- NUVB $101.21
- TRNS $10.74
- Revenue Next Year
- NUVB $410.28
- TRNS $6.60
- P/E Ratio
- NUVB N/A
- TRNS $57.25
- Revenue Growth
- NUVB N/A
- TRNS 7.30
- 52 Week Low
- NUVB $1.54
- TRNS $67.56
- 52 Week High
- NUVB $3.97
- TRNS $147.12
- Technical
- Relative Strength Index (RSI)
- NUVB 51.54
- TRNS 64.47
- Support Level
- NUVB $1.87
- TRNS $82.16
- Resistance Level
- NUVB $2.10
- TRNS $89.34
- Average True Range (ATR)
- NUVB 0.16
- TRNS 3.22
- MACD
- NUVB 0.01
- TRNS 1.02
- Stochastic Oscillator
- NUVB 91.23
- TRNS 97.45
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About TRNS Transcat Inc.
Transcat Inc is involved in providing calibration and laboratory instrument services and distribution of test, measurement, and control instrumentation. Its product and services portfolio consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, etc. The firm has Service and Distribution operating segments. It derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Estech, FLIR, Fluke, Keysight, and Megger among others. It serves to pharmaceutical, industrial manufacturing, energy, and chemical process industries.